BCL2 and breast carcinoma: Knockdown of PERK promotes survival of luminal breast cancer cells treated with a combination of lapatinib (a tyrosine kinase inhibitor) and obatoclax (a pro-survival BCL-2 family inhibitor) by reducing pro-death autophagy [73].